Deep Track Capital LP Acquires 1,949,942 Shares of enGene Holdings Inc. (NASDAQ:ENGN)

Deep Track Capital LP lifted its holdings in enGene Holdings Inc. (NASDAQ:ENGN) by 74.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 4,557,575 shares of the company’s stock after acquiring an additional 1,949,942 shares during the quarter. Deep Track Capital LP owned 10.31% of enGene worth $30,308,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. Franklin Resources Inc. lifted its stake in enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in shares of enGene in the 4th quarter valued at about $69,000. Blue Owl Capital Holdings LP boosted its holdings in enGene by 3.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock valued at $21,014,000 after acquiring an additional 101,006 shares during the period. Jane Street Group LLC purchased a new stake in enGene during the 4th quarter valued at about $93,000. Finally, Cubist Systematic Strategies LLC grew its position in enGene by 15.7% during the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock worth $102,000 after acquiring an additional 2,080 shares during the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Price Performance

ENGN stock opened at $3.69 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The firm has a 50 day moving average price of $4.55 and a 200-day moving average price of $6.40. enGene Holdings Inc. has a 52-week low of $3.50 and a 52-week high of $15.50. The firm has a market capitalization of $187.85 million, a price-to-earnings ratio of -6.35 and a beta of -0.36.

Wall Street Analysts Forecast Growth

ENGN has been the subject of a number of analyst reports. Piper Sandler initiated coverage on enGene in a research note on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of enGene in a report on Tuesday, March 11th. JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of enGene in a research note on Tuesday, April 29th. UBS Group lowered shares of enGene from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $34.00 to $7.00 in a report on Friday, February 14th. Finally, Morgan Stanley reduced their price target on enGene from $37.00 to $34.00 and set an “overweight” rating on the stock in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, enGene has an average rating of “Buy” and an average price target of $23.29.

enGene Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.